Metabolic syndrome in patients with schizophrenia and antipsychotic treatment

Eva Aguilar, Ramón Coronas, Assumpta Caixàs

Producció científica: Contribució a revistaArticle de revisióRecercaAvaluat per experts

12 Cites (Scopus)

Resum

Patients with schizophrenia have a shorter life expectancy and their risk of dying from a cardiovascular disease is higher than the general population. Both facts have been attributed to the raised presence of metabolic syndrome. There is a big amount of scientific publications that deals with the relationship between schizophrenia, antipsychotic treatment, and the development of metabolic syndrome. There is also information about recommendations and clinical guides to achieve an adequate prevention, screening, and treatment of the disease. The aim of this review is to update the current information about this issue and to understand related etiologic factors, differences between antipsychotic drugs, and the current recommendations for patient's care. © 2011 Elsevier Espana, S.L. Todos los derechos reservados.
Idioma originalAnglès
Pàgines (de-a)542-546
Nombre de pàgines4
RevistaMedicina Clinica
Volum139
Número12
DOIs
Estat de la publicacióPublicada - 17 de nov. 2012

Fingerprint

Navegar pels temes de recerca de 'Metabolic syndrome in patients with schizophrenia and antipsychotic treatment'. Junts formen un fingerprint únic.

Com citar-ho